BTK and B-cell chronic lymphocytic leukemia: Although the exact mechanisms of resistance in these cases remain unclear, it can be speculated that mutations in signalling components downstream of BTK, in the mitogen-sctivated protein kinase (MAPK) pathway, for example, or dysregulation of another pro-survival pathway may also confer resistance to ibrutinib in CLL.